Citigroup
BTAI icon

Citigroup’s BioXcel Therapeutics BTAI Stock Holding History

Citigroup’s Portfolio BTAI Stock Details BTAI Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		– Sell
-12,079
Closed -$19.3K – 5969
2025
Q4 		$19.3K Buy
12,079
+11,724
+3,303% +$24.2K ﹤0.01% 4882
2025
Q3 		$909 Buy
+355
New +$1.12K ﹤0.01% 5639
2024
Q4 		– Hold
0
– -$2 – 5845
2024
Q3 		– Sell
-3,486
Closed -$46.8K – 5647
2024
Q2 		$71.4K Buy
3,486
+3,266
+1,485% +$109K ﹤0.01% 4386
2024
Q1 		$9.91K Buy
220
+39
+22% +$1.86K ﹤0.01% 5202
2023
Q4 		$8.53K Sell
181
-1,340
-88% -$74.5K ﹤0.01% 5229
2023
Q3 		$61.6K Sell
1,521
-2,233
-59% -$226K ﹤0.01% 4069
2023
Q2 		$400K Sell
3,754
-3,682
-50% -$1.23M ﹤0.01% 3523
2023
Q1 		$2.22M Buy
7,436
+7,397
+18,967% +$3.16M ﹤0.01% 1947
2022
Q4 		$13.3K Sell
39
-9
-19% -$2.18K ﹤0.01% 4741
2022
Q3 		$9K Sell
48
-67
-58% -$15.6K ﹤0.01% 5020
2022
Q2 		$24K Sell
115
-845
-88% -$178K ﹤0.01% 4885
2022
Q1 		$321K Sell
960
-3,887
-80% -$1.13M ﹤0.01% 3795
2021
Q4 		$1.58M Buy
4,847
+2,387
+97% +$1.02M ﹤0.01% 2811
2021
Q3 		$1.2M Sell
2,460
-4,066
-62% -$1.79M ﹤0.01% 2950
2021
Q2 		$3.03M Buy
6,526
+1,080
+20% +$589K ﹤0.01% 2327
2021
Q1 		$3.76M Buy
5,446
+5,266
+2,926% +$4.24M ﹤0.01% 2013
2020
Q4 		$133K Buy
180
+87
+94% +$67.8K ﹤0.01% 5300
2020
Q3 		$65K Sell
93
-918
-91% -$689K ﹤0.01% 5415
2020
Q2 		$857K Buy
1,011
+881
+678% +$575K ﹤0.01% 3720
2020
Q1 		$46K Buy
130
+43
+49% +$15.5K ﹤0.01% 6032
2019
Q4 		$20K Buy
87
+68
+358% +$6.84K ﹤0.01% 6928
2019
Q3 		$2K Sell
19
-87
-82% -$13.7K ﹤0.01% 7524
2019
Q2 		$18K Buy
106
+6
+6% +$1.02K ﹤0.01% 7119
2019
Q1 		$16K Buy
+100
New +$12.3K ﹤0.01% 7056

Other funds holding BTAI

Millennium Management
Millennium Management New York $240B AUM 35.51% 1-Year Est. Return
AC
Armistice Capital New York $5.62B AUM 36.06% 1-Year Est. Return
OCM
Oaktree Capital Management Los Angeles, California $6.56B AUM 42.97% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
VCM
Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM
Jones Financial Companies
Jones Financial Companies Des Peres, Missouri $208B AUM 16.12% 1-Year Est. Return
Man Group
Man Group London, United Kingdom $55.1B AUM 24.23% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
VFT
Vanguard Fiduciary Trust Malvern, Pennsylvania $396B AUM

Citigroup's BTAI Position: Q1 2026 in Review

Citigroup sold out of BioXcel Therapeutics (BTAI) in Q1 2026, closing a stake of 12,079 shares — an estimated $19.3K sold.

Citigroup first reported a position in BTAI in Q1 2019 and held it in 24 quarters. The position peaked at $3.76M in Q1 2021. 40 funds tracked by Wall St. Rank hold BTAI as of Q1 2026.

  • Citigroup reported no remaining BioXcel Therapeutics position as of Q1 2026 after selling out during the quarter.
  • Citigroup sold 12,079 BioXcel Therapeutics shares in Q1 2026, an estimated $19.3K.
  • Citigroup first reported a position in BioXcel Therapeutics in Q1 2019 and held it in 24 quarters.
  • Citigroup's BioXcel Therapeutics position peaked at $3.76M in Q1 2021.
  • 40 funds tracked by Wall St. Rank held BioXcel Therapeutics as of Q1 2026.

Based on Citigroup's 13F filing for Q1 2026, filed 11 May 2026.